AVITA Medical Announces Listing on Nasdaq – Trading of American Depository Shares to begin under the ticker symbol “RCEL” on October 1st

/in

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 30 September, 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced that its American Depositary Shares (“ADS”) have been approved to list on the Nasdaq Capital Market […]

Read more

MULTI-WELL PLATE PATENT GRANTED

/in

Link to Full Article The European patent office issued patent EP2812424 on 28th August 2019. The patented invention is a multi-well plate containing a scaffold layer which provides a porous three-dimensional network of polymer nanofibres suitable for growing cells in 3D and the process for fabricating the multi-well assay plate. The Electrospinning Company manufactures the Mimetix® range of […]

Read more

New Data Published in Aesthetic Plastic Surgery Explores the Use of the RECELL System in Combination with Dermabrasion to Treat Acne Scars

/in

Link to Full Article Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions Valencia, Calif., USA, and Melbourne, Australia, 19 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the healing properties of a […]

Read more

Dementia kit: tech leads the charge to protect people’s independence

/in

Lindsay Cook 18 September 2019 – Dementia costs more than it should. With better, earlier diagnosis and the clever use of technology, the UK could save £100bn in the next 15 years, according to the International Longevity Centre.  The alternative: do nothing, put Britain’s health and social care system under intolerable strain and leave hundreds […]

Read more

AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction

/in

Link to Full Article First RECELL System clinical trial in the U.S. focused on acute soft tissue injuries, defects, and reconstruction; study expected to commence within next 6 months Valencia, Calif., USA, and Melbourne, Australia, 17 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization […]

Read more

Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa

/in

Link to Full Article Initial clinical emphasis on difficult-to-treat respiratory infections in cystic fibrosis patients MARINA DEL REY, Calif., Sept. 12, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the “Company” or “Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the Company has developed a new synthetic phage […]

Read more

Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections

/in

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the company”) Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections Collaboration to investigate antimicrobial candidates from the company’s XF drug platform against microbial infections of the eye  Marks the fourth research grant Destiny […]

Read more

Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections

/in

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the company”) Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections Collaboration to investigate antimicrobial candidates from the company’s XF drug platform against microbial infections of the eye  Marks the fourth research grant Destiny […]

Read more

AVITA Medical Added to the S&P/ASX 300 Index

/in

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 6 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, acknowledges that the company will be added to the S&P/ASX 300 index, effective upon market open on 23 September 2019. “We are pleased to be included in the S&P/ASX 300 […]

Read more